• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neurocrine Biosciences, Inc. - Common Stock (NQ: NBIX )

    139.44 +0.41 (+0.29%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 602,689
    Open 139.09
    Bid (Size) 138.10 (1)
    Ask (Size) 143.00 (1)
    Prev. Close 139.03
    Today's Range 138.34 - 139.82
    52wk Range 110.95 - 157.98
    Shares Outstanding 101,200,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Neurocrine Biosciences Stock Sees RS Rating Upgrade
    Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
    Via Investor's Business Daily
    While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable.
    NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. 
    Via Chartmill

    Performance

    YTD
    +5.85%
    +5.85%
    1 Month
    +10.15%
    +10.15%
    3 Month
    +21.19%
    +21.19%
    6 Month
    +1.29%
    +1.29%
    1 Year
    +5.52%
    +5.52%

    More News

    Read More
    Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
    Via Benzinga
    What Analysts Are Saying About Neurocrine Biosciences Stock
    Via Benzinga
    Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
    Via Benzinga
    Exposures Product Safety
    NASDAQ:NBIX qualifies as a high growth stock and is consolidating.
    Via Chartmill
    NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
    Via Chartmill
    NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
    Via Chartmill
    Neurocrine Wins FDA Approval For Genetic Disorder Drug
    Via Investor's Business Daily
    Exposures Product Safety
    Screening For Black Friday Bargains In The Stock Market
    Via Benzinga
    For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
    Via Chartmill
    NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases.
    Via Chartmill
    AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
    Via Benzinga
    In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences
    Via Benzinga
    Decoding 19 Analyst Evaluations For Neurocrine Biosciences
    Via Benzinga
    NASDAQ:NBIX, a growth stock which is not overvalued.
    Via Chartmill
    NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
    Via Chartmill
    NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals.
    Via Chartmill
    Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
    Via Chartmill
    Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know
    Via Benzinga
    "Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins
    Via The Motley Fool
    Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
    Via Chartmill
    For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals.
    Via Chartmill
    Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
    Via Benzinga
    Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.